Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: A twelve-year experience

Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension

(2010) N. Ruperto et al.   ANNALS OF THE RHEUMATIC DISEASES

Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?

(2010) B. Saleem et al.   ANNALS OF THE RHEUMATIC DISEASES

Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study

(2010) Y. Tanaka et al.   ANNALS OF THE RHEUMATIC DISEASES

Tumor necrosis factor α blockers and malignancy in children: Forty-eight cases reported to the food and drug administration

(2010) Peter Diak et al.   ARTHRITIS AND RHEUMATISM

Discontinuation of Etanercept After Successful Treatment in Patients with Juvenile Idiopathic Arthritis

(2010) A. REMESAL et al.   JOURNAL OF RHEUMATOLOGY

When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis

(2009) F H M Prince et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical Remission in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Anti-Tumor Necrosis Factor Agents

(2009) R. A.G. RUSSO et al.   JOURNAL OF RHEUMATOLOGY

Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis

(2008) Daniel J. Lovell et al.   ARTHRITIS AND RHEUMATISM